ACC/AHA Endorse Cardiovascular Computed Tomography Angiography (CCTA) in New Chest Pain Guidelines
BOSTON–(BUSINESS WIRE)–Elucid, a medical technology company developing AI software to enable cardiovascular disease detection, expects newly issued guidelines will be a catalyst for non-invasive image, revolutionizing the way patients with coronary artery disease are diagnosed and treated.
In a highly anticipated document published online yesterday in Circulation and the Journal of the American College of Cardiology, the Joint Committee on Clinical Practice Guidelines for the American College of Cardiology & American Heart Association released new clinical practice guidelines for managing patients with Acute and Stable chest pain.
Backed by strong clinical evidence in favor of CCTA, the committee made sweeping revisions elevating the role of this important non-invasive diagnostic tool in the clinical pathway for patients with suspected coronary artery disease. For intermediate-risk patients with no known CAD, CCTA is now a class I recommendation for excluding atherosclerotic plaque and obstructive CAD (level of evidence A). If there is evidence of a stenosis (40-90%), or CCTA is inconclusive, FFR-CT can be used to diagnose vessel-specific ischemia or aid clinical decisions (class 2a, level of evidence B).
Gregg W. Stone, MD, Director of Academic Affairs for the Mount Sinai Heart Health System, New York, NY, said “the recommendations for CCTA were based on the outcomes of rigorously performed clinical studies, both randomized trials and registries. CCTA delineation of the extent of atherosclerosis, coupled with FFR-CT to assess ischemia and plaque composition analysis to assess lesion vulnerability, should comprehensively risk stratify patients with suspected and established coronary artery disease, and enable development of novel approaches and therapies to prevent acute coronary syndromes, myocardial infarction and cardiac death.”
“The evidence for CCTA is overwhelmingly positive and we are excited to see the guideline changes enacted with this document” said Blake Richards, Elucid CEO, “Congratulations to the committee for an exhaustive evaluation and excellent publication. The use of scientific imaging supported by artificial intelligence to quantitate vessel wall biology will help the field move forward and save millions of lives each year.”
The guidelines are endorsed by the American Society of Echocardiography (ASE), American College of Chest Physicians (CHEST), Society for Academic Emergency Medicine (SAEM), Society of Cardiovascular Computed Tomography (SCCT), and Society for Cardiovascular Magnetic Resonance (SCMR).
Elucid is a Boston-based medical technology company using uniquely interpretable and validated AI to provide physicians with a cost-effective means to optimize treatment decisions for patients with known or suspected cardiovascular disease. Advanced clinical insights from ElucidVivo equip physicians with critical information designed to enable precision medicine. ElucidVivo is the first FDA-Cleared and CE-marked non-invasive software to quantify atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core. The company recently published studies for its derivation of fractional flow reserve (FFR-CT) based on the vasodilative capacity of the vessel wall and estimation of coding and non-coding RNA transcripts (“Virtual Transcriptomics”). This unique information informs better treatment decisions by physicians leading to better patient outcomes, improved quality of care, and reduced healthcare costs. The ElucidVivo software is available for commercial use in the U.S. and Europe. To learn more visit https://www.elucidvivo.com/ and follow us on LinkedIn.
Chief Commercial Officer
Phone: +1 617 738 3515